⚠ Evidence warning: Clinical trials or other evidence do not support the claim that Turkey Tail, or the shiitake extract AHCC (active hexose correlated compound), clears persistent human papillomavirus (HPV) infection and reverses low-grade cervical lesions. This page keeps it as a report of what people, websites or other media say.

Turkey Tail for Human Papillomavirus (HPV) and Cervical Dysplasia

human papillomavirus and Cervical Dysplasia — scientific infographic poster

Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide; over 80% of sexually active adults will be exposed during their lifetime. The majority of infections clear spontaneously within 12-24 months via natural killer (NK) cell and cytotoxic T-cell-mediated immune surveillance. A minority (approximately 10%) persist as chronic infection and become the precursor to cervical, anal, oropharyngeal, vulvar, vaginal, and penile cancers. The clinical interest in medicinal mushroom polysaccharides for human papillomavirus management stems from small pilot studies of AHCC (active hexose correlated compound, a related shiitake-derived polysaccharide-rich extract sharing immune-modulating pharmacology with Turkey Tail), in which 4 of 6 women with persistent high-risk human papillomavirus had confirmed clearance after 3-6 months of AHCC 3 g a day (Smith 2019), and from a 2022 randomized placebo-controlled trial of AHCC by the same group. The proposed mechanism is enhancement of endogenous natural killer cell-mediated and dendritic cell-coordinated viral clearance from infected cervical keratinocytes. Direct Turkey Tail human papillomavirus studies are more limited: a preliminary 2-month oral study in people with gingivitis (Donatini 2014) and trials of a Coriolus versicolor-based vaginal gel.


Table of Contents

  1. Human Papillomavirus Biology and Natural History
  2. Why Some Infections Persist and Most Clear
  3. The First AHCC Pilot Studies (Smith 2019)
  4. The 2022 Phase II Randomized Trial of AHCC
  5. Direct Coriolus versicolor (Turkey Tail) Studies
  6. Turkey Tail as a Vaginal Gel: The PALOMA Trial
  7. Mechanism: Natural Killer Cell-Mediated Keratinocyte Clearance
  8. Cervical Dysplasia Staging & Management
  9. Doses Used in the Trials and What They Found
  10. Integration with Conventional Care
  11. Other Human Papillomavirus-Associated Sites (Oropharyngeal, Anal)
  12. Cautions and Limitations of the Evidence
  13. Key Research Papers
  14. Connections
  15. Featured Videos

Human Papillomavirus Biology and Natural History

Human papillomaviruses are small, non-enveloped, double-stranded DNA viruses that infect basal keratinocytes of stratified squamous epithelium. Over 200 human papillomavirus types have been characterized, of which approximately 40 infect the anogenital tract and 14 are designated "high-risk" because of their oncogenic potential. The two most important high-risk types are HPV-16 (cause of approximately 50% of cervical cancers worldwide) and HPV-18 (cause of approximately 15-20% of cervical cancers). Other high-risk types include HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.

The natural history of human papillomavirus infection involves several stages:

  1. Initial infection — human papillomavirus enters basal keratinocytes through microabrasions in the epithelium during sexual contact
  2. Productive infection — virus replicates in the differentiating epithelium, producing infectious virions in the superficial layers that shed into bodily secretions
  3. Spontaneous clearance — in 80-90% of cases, the immune system clears the infection within 12-24 months
  4. Persistent infection — in approximately 10% of cases, the virus persists and can be detected on repeat testing more than 24 months later. Persistence is the strongest risk factor for progression to dysplasia and cancer.
  5. Cervical intraepithelial neoplasia (CIN) — persistent high-risk human papillomavirus infection can drive progression through CIN 1 (mild dysplasia), CIN 2 (moderate), and CIN 3 (severe)
  6. Invasive cancer — CIN 3 lesions can progress to invasive cervical cancer over 5-15 years if untreated; this transition is the rate-limiting step that screening (Pap smear, human papillomavirus testing) is designed to interrupt

The clinical opportunity for immune-modulating intervention is concentrated in stages 3-5: at the persistent-infection / low-grade-dysplasia transition, where the immune system has demonstrably failed to clear the virus on its own and there is still an opportunity to restore that clearance before higher-grade lesions develop. This is the window targeted by the AHCC and Turkey Tail trials.

Back to Table of Contents

Why Some Infections Persist and Most Clear

The 80-90% spontaneous clearance rate vs the 10% persistence rate is one of the most important questions in human papillomavirus biology. The factors identified as contributing to persistence include:

The therapeutic premise of immune-modulating therapy is that some persistent infections result from suboptimal natural killer cell and dendritic cell function, and that restoring this function can permit clearance even after years of viral persistence. The clinical trial data supports this premise, at least for a meaningful subset of patients.

Back to Table of Contents

The First AHCC Pilot Studies (Smith 2019)

The first published human data on AHCC for human papillomavirus come from a 2019 paper in Frontiers in Oncology by Judith Smith and colleagues, which took the extract “from bench to bedside”: cervical cancer cells in the dish, a mouse study, and two small pilot studies in women.

Results:

The pilots were small and had no placebo group, so their results are preliminary — the authors’ own word. They noted that a confirmatory phase II randomized, double-blinded, placebo-controlled study was ongoing; that trial is described in the next section.

Note: AHCC (active hexose correlated compound) is not Turkey Tail. The 2022 trial describes it as a proprietary, standardized extract of cultured shiitake (Lentinula edodes) mycelia. Its bioactive constituents are alpha-glucans and beta-glucans, with mechanism of action that overlaps with but is not identical to Turkey Tail polysaccharide-K (PSK) / polysaccharopeptide (PSP). Because AHCC is the extract with the formal human papillomavirus clinical trial data, this discussion focuses on AHCC results while noting the mechanistic convergence with Turkey Tail. Direct Turkey Tail human papillomavirus studies are more limited (Donatini 2014, a preliminary 2-month oral study, and the vaginal-gel studies described below).

Back to Table of Contents

The 2022 Phase II Randomized Trial of AHCC

Judith Smith has been the principal investigator on the more formal follow-up trials of AHCC for human papillomavirus. The Smith 2022 study in Frontiers in Oncology reported a phase II randomized, double-blind, placebo-controlled trial in 50 women with persistent high-risk human papillomavirus infection.

Smith 2022 design:

Results:

The Smith 2022 trial is the most rigorous evidence to date for a medicinal mushroom polysaccharide intervention in human papillomavirus. Within the trial, 63.6% of AHCC-treated women were negative at 6 months, against 10.5% of placebo-treated women at 12 months. The immune correlate the authors report — suppression of interferon-beta together with a rise in T lymphocytes and interferon-gamma — is consistent with the immune-mediated viral clearance hypothesis.

A larger Phase III randomized trial is needed to confirm these findings and to define the optimal duration of treatment, the optimal patient population, and the durability of clearance after stopping treatment; the authors write that “The duration of AHCC supplementation required beyond the first negative result needs more evaluation.”

Back to Table of Contents

Direct Coriolus versicolor (Turkey Tail) Studies

The direct Turkey Tail (Coriolus versicolor) human papillomavirus evidence base is smaller than the AHCC evidence:

Most of the European Turkey Tail data now concern a Coriolus versicolor-based vaginal gel rather than an oral supplement. A 2026 scoping review of the gel found five eligible studies: one randomized trial of 91 women, one sub-analysis of that trial (41 women), and three cohort studies of 183, 192 and 21 women. It reported regression rates of 76.1–84.9% in treated women compared with 40.8–64.5% in untreated controls, and no serious adverse events, and it describes the gel’s efficacy and safety as “promising but preliminary.”

The oral studies are small and short, so the evidence is weaker than the randomized AHCC data, though the direction of effect is consistent with it.

Back to Table of Contents

Turkey Tail as a Vaginal Gel: The PALOMA Trial

The randomized trial of a Turkey Tail product for cervical human papillomavirus used a Coriolus versicolor-based vaginal gel, not a capsule. The PALOMA study (2021) was a multicenter, open-label, randomized trial in 91 HPV-positive women with low-grade Pap smear changes and matching colposcopy, comparing the gel with a watchful-waiting (no treatment) approach.

The trial was open-label (everyone knew who received the gel), and the 2026 FIGO/IGCS statement described in the integration section raises further concerns about the gel studies.

Back to Table of Contents

Mechanism: Natural Killer Cell-Mediated Keratinocyte Clearance

The mechanism by which medicinal mushroom polysaccharides facilitate human papillomavirus clearance is the same natural killer cell potentiation mechanism discussed at length in our immune surveillance deep-dive, with specific application to human papillomavirus-infected cervical keratinocytes.

The key steps:

  1. Human papillomavirus-infected keratinocytes downregulate major histocompatibility complex (MHC) class I — human papillomavirus E5, E6, and E7 proteins reduce surface MHC class I expression as an immune-evasion strategy. This protects against cytotoxic T-cell recognition but creates a "missing self" signature that natural killer cells specifically target.
  2. Natural killer cells in the cervical mucosa recognize human papillomavirus-infected cells — intraepithelial natural killer cells expressing activating receptors (NKG2D, NKp30, NKp44, NKp46) recognize stress ligands on infected keratinocytes
  3. Natural killer cells deliver cytotoxic granules — perforin and granzyme B induce apoptosis in the target cell, eliminating the infected keratinocyte before it can produce more virions
  4. Dendritic cells acquire viral antigens from apoptotic cells — cross-presentation of human papillomavirus antigens on dendritic cell MHC class I drives expansion of human papillomavirus-specific cytotoxic T cells
  5. Human papillomavirus-specific T cells provide durable surveillance — memory CD8+ T cells specific for human papillomavirus E6 and E7 oncoproteins provide long-term protection against recurrence

Turkey Tail and AHCC act at step 2-3 by potentiating natural killer cell activity and at step 4 by enhancing dendritic cell antigen presentation. The net effect is acceleration of the same physiologic clearance mechanism that successfully clears human papillomavirus in the 80-90% of immunocompetent individuals who never develop persistent infection.

This is important conceptually: the mushroom extracts are not directly antiviral in the sense of acyclovir for herpes. They do not inhibit human papillomavirus replication, do not target viral proteins, and have no direct effect on infected cells. They restore the host immune-mediated clearance mechanism, which then does the actual work of eliminating the infection.

Back to Table of Contents

Cervical Dysplasia Staging & Management

The staging system and the standard-of-care management for human papillomavirus-related cervical changes:

The Smith 2022 AHCC trial enrolled women over 30 years of age with confirmed persistent high-risk human papillomavirus infection for more than 2 years; its abstract does not describe enrolment by cytology category. The PALOMA gel trial enrolled women with low-grade Pap smear changes. For HSIL/CIN 2-3 or invasive cancer, conventional excisional or oncologic treatment is the standard of care.

Back to Table of Contents

Doses Used in the Trials and What They Found

The doses and durations the human studies used, and related points from the evidence:

What the trials found:

Back to Table of Contents

Integration with Conventional Care

Turkey Tail and AHCC have been studied as additions to, not substitutes for, standard human papillomavirus / cervical dysplasia management. How they relate to conventional care:

  1. Surveillance is the standard of care — human papillomavirus testing, cytology, colposcopy, and biopsy as indicated
  2. Interactions — there is no documented negative interaction between medicinal mushroom polysaccharides and standard human papillomavirus management.
  3. HSIL/CIN 2-3 carries a real progression risk — the progression risk to invasive cancer is real, and definitive excisional treatment is the standard management when indicated; a supplement trial does not remove that risk.
  4. Human papillomavirus vaccination remains the gold standard primary prevention for unexposed individuals. Turkey Tail does not substitute for human papillomavirus vaccination, and in women with human papillomavirus exposure vaccination can still prevent infection with types they have not yet been exposed to.
  5. The window the supplement studies targeted — persistent infection with normal-to-low-grade cytology, where conventional medicine offers watchful waiting and the immune-mediated clearance mechanism is what the supplements are meant to support.

In 2026 FIGO (the International Federation of Gynecology and Obstetrics) and the International Gynecologic Cancer Society (IGCS) issued a position statement on topical treatments for high-risk human papillomavirus and LSIL, including Coriolus versicolor-based vaginal gels. They found that “No randomized controlled trial has been adequately designed or powered” to evaluate the effect of topical therapies on the prevention of histologically confirmed HSIL/CIN3+. For the Coriolus versicolor-based and silicon dioxide/selenite-based gels, they reported “retrospective trial registration, industry funding, and misinterpretation of findings consistent with the spin phenomenon.” The statement says FIGO and IGCS “do not endorse the routine clinical use of any currently available topical agent for HR-HPV infection or LSIL” and that evidence-based surveillance remains the standard of care.

For more on human papillomavirus management broadly, see our human papillomavirus page.

Back to Table of Contents

Other Human Papillomavirus-Associated Sites (Oropharyngeal, Anal)

Human papillomavirus does not infect only the cervix. The same high-risk types cause cancers of the oropharynx (rising rapidly in incidence in developed countries, now exceeding cervical cancer in some Western populations), anus, vulva, vagina, and penis. The Donatini 2014 preliminary randomized study specifically addressed oral human papillomavirus with combined Coriolus / Ganoderma therapy for 2 months in people with gingivitis, reporting 88% clearance of HPV-16/18 on mouth swabs, against 5% in the comparison group.

The immune mechanism of clearance is the same at all anatomic sites: natural killer cell-mediated elimination of infected keratinocytes followed by dendritic cell-coordinated adaptive responses. Patients with oropharyngeal human papillomavirus (often detected on incidental dental or ear, nose and throat (ENT) examination) or anal human papillomavirus (detected on screening anal Pap in high-risk populations) fall outside what the cervical trials studied, and the formal clinical trial evidence for these sites is thinner.

Back to Table of Contents

Cautions and Limitations of the Evidence

Back to Table of Contents

Key Research Papers

  1. Smith JA, Gaikwad AA, Mathew L, Rech B, Faro JP, Lucci JA 3rd, Bai Y, Olsen RJ, Byrd TT (2022). AHCC® Supplementation to Support Immune Function to Clear Persistent Human Papillomavirus Infections. Frontiers in Oncology 12:881902. — PubMed PMID: 35814366
  2. Smith JA, Mathew L, Gaikwad A, Rech B, Burney MN, Faro JP, Lucci JA 3rd, Bai Y, Olsen RJ, Byrd TT (2019). From Bench to Bedside: Evaluation of AHCC Supplementation to Modulate the Host Immunity to Clear High-Risk Human Papillomavirus Infections. Frontiers in Oncology 9:173. — PubMed PMID: 30949451
  3. Donatini B (2014). Control of oral human papillomavirus (HPV) by medicinal mushrooms, Trametes versicolor and Ganoderma lucidum: a preliminary clinical trial. International Journal of Medicinal Mushrooms. — PubMed PMID: 25271984
  4. Serrano L, López AC, González SP, Palacios S, Dexeus D, Centeno-Mediavilla C, Coronado P, de la Fuente J, López JA, Vanrell C, Cortés J (2021). Efficacy of a Coriolus versicolor-Based Vaginal Gel in Women With Human Papillomavirus-Dependent Cervical Lesions: The PALOMA Study. Journal of Lower Genital Tract Disease. — PubMed PMID: 33746195
  5. Højen IB, Kristensen MK, Bertelsen VM, Tranberg M, Petersen LK, Andersen B, Bor P (2026). Effect of coriolus versicolor-based vaginal gel on clearance of human papillomavirus and cervical dysplasia - a scoping review. BMC Women’s Health. — PubMed PMID: 41507892
  6. Pareja R, Heredia F, Sánchez-Díaz E, et al. (2026). FIGO/IGCS Statement on the efficacy of topical treatments for high-risk human papillomavirus in preventing CIN 3+ lesions. International Journal of Gynecological Cancer. — PubMed PMID: 42680632
  7. Walsh CJ, Friedman JC, Piper C, Conageski C (2024). A Scoping Review of Complementary and Alternative Medicine for Human Papillomavirus Infections and Cervical Dysplasia. Journal of Lower Genital Tract Disease. — PubMed PMID: 38697129
  8. Stanley M (2010). HPV - immune response to infection and vaccination. Infectious Agents and Cancer. — PubMed PMID: 20961432
  9. Schiffman M et al. (2016). Carcinogenic human papillomavirus infection. Nature Reviews Disease Primers. — PubMed PMID: 27905473
  10. Sasagawa T, Takagi H, Makinoda S (2012). Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer. Journal of Infection and Chemotherapy. — PubMed PMID: 23117294
  11. Cuschieri KS, Cubie HA, Whitley MW, Gilkison G, Arends MJ, Graham C, McGoogan E (2005). Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. Journal of Clinical Pathology. — PubMed PMID: 16126875

PubMed Topic Searches

  1. PubMed: AHCC HPV
  2. PubMed: Coriolus HPV cervical
  3. PubMed: Mushroom HPV clearance
  4. PubMed: NK cell cervical dysplasia
  5. PubMed: CIN immune clearance

Back to Table of Contents

Connections

Back to Table of Contents